Prognostic and Predictive Significance of mRNA Expression of ABC-transporter Genes in Patients with Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Prognostic and Predictive Significance of mRNA Expression of ABC-transporter Genes in Patients with Non-small Cell Lung Cancer

Published:2022-11-27 Issue:4 Volume:11 Page:253-260
ISSN:2658-5049
Container-title:Drug development & registration
language:
Short-container-title:Razrabotka i registraciâ lekarstvennyh sredstv

Author:

Tsyganov M. M.¹^ORCID,Ibragimova M. K.²^ORCID,Rodionov E. O.³^ORCID,Frolova A. A.³^ORCID,Miller S. V.³^ORCID,Cheremisina O. V.³^ORCID,Tuzikov S. A.³^ORCID,Litvyakov N. V.³^ORCID

Affiliation:

1. Research Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Center for Medicine by the Russian Academy of Sciences»; Siberian State Medical University, SSMU

2. Research Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Center for Medicine by the Russian Academy of Sciences»; The National Research Tomsk State University, TSU; Siberian State Medical University, SSMU

3. Research Institute of Oncology, Federal State Budgetary Scientific Institution «Tomsk National Research Center for Medicine by the Russian Academy of Sciences»

Abstract

Introduction. To date, one of the reasons for the ineffectiveness of chemotherapy in various malignant neoplasms, including lung cancer, is the formation of the multidrug resistance (MDR) phenotype in tumor cells, which is caused by the expression of ABC transporter genes.Aim. The aim of this work was to assess the expression of ABC-transporter genes during chemotherapy and to analyze the relationship with the effectiveness of chemotherapy and prognosis of the disease.Materials and methods. We used biopsy and surgical material from 91 patients with stage IIB–IIIA non-small cell lung cancer (NSCLC). The treatment regimen included: 2 courses of neoadjuvant chemotherapy (NAC), surgery and 3 courses of adjuvant chemotherapy (ACT) with platinum doublets. RNA was isolated from the samples, followed by quantitative PCR to assess the expression of genes ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, ABCG2.Results and discussion. It was shown that the level of expression of the studied genes was not associated with the effect of NAC in patients with lung cancer, except for the ABCC5 gene, which showed a relationship at the level of a pronounced trend (p = 0.07). It was also shown that in the group of patients with an objective response to chemotherapy, the frequency of decreased expression of the ABCC1 (p = 0.01) and ABCC5 (p = 0.004) genes was statistically significantly higher than in the group of patients with stabilization. Further, using the Kaplan – Meier method, it was found that a decrease in expression is associated with high rates of metastatic-free survival (MFS). The highest rates of 5-year MFS (more than 85 %) are observed in patients with a decrease in the expression of the ABCB1 and ABCG2 genes, log-rank test p = 0.0007 and p = 0.002, respectively.Conclusion. Thus, it has been shown that changes in the expression of ABC transporter genes are associated with the effectiveness of chemotherapy and the prognosis of the disease. The data obtained can be used as a basis for the detection of potential drug targets.

Publisher

Center of Pharmaceutical Analytics Ltd

Subject

Drug Discovery,Pharmaceutical Science

Reference21 articles.

1. Duma N., Santana-Davila R., Molina J. R. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clinic Proceedings. 2019;94(8):1623–1640. DOI: 10.1016/j.mayocp.2019.01.013.

2. Brandt W. S., Yan W., Zhou J., Tan K. S., Montecalvo J., Park B. J., Adusumilli P. S., Huang J., Bott M. J., Rusch V. W., Molena D., Travis W. D., Kris M. G., Chaft J. E., Jones D. R. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: a propensity-matched analysis. The Journal of Thoracic and Cardiovascular Surgery. 2019;157(2):743–753. DOI: 10.1016/j.jtcvs.2018.09.098.

3. Maclean M., Luo X., Wang S., Kernstine K., Gerber D. E., Xie Y. Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database. Oncotarget. 2018;9(36):24470–24479. DOI: 10.18632/oncotarget.25327.

4. Pisters K., Kris M. G., Gralla R. J., Zaman M. B., Heelan R. T., Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. Journal of Clinical Oncology. 1993;11(9):1757–1762. DOI: 10.1200/JCO.1993.11.9.1757.

5. Roth J. A., Fossella F., Komaki R., Ryan M. B., Putnam Jr. J., Lee J. S., Dhingra H., De Caro L., Chasen M., McGavran M., Atkinson E. N., Hong W. K. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. JNCI: Journal of the National Cancer Institute. 1994;86(9):673–680. DOI: 10.1093/jnci/86.9.673.